Ocean Power Technologies, Inc. (OPTT) and Lockheed Martin (LMT) announced today that they have entered into a teaming agreement with the goal of developing a 19 megawatt wave-energy project in Victoria, Australia, one of the largest wave-energy projects announced to date. Lockheed Martin will assist with the design of Ocean Power Technologies’ (OPT) PowerBuoy® technology, […]
ICPA, SCFR: Last-minute & After-Hours News
IC Places, Inc. (ICPA) announced today that it has entered into a distribution partnership with Smarter Comics, named “One of the 100 Most Brilliant Ideas of 2012” by Entrepreneur Magazine in June 2012. Smarter Comics takes classic and modern Self Help Books and transforms them into a comic book format. The first Smarter Comics’s book offered […]
WFR, ATPG, ANTH: Today’s Movers for Tomorrow’s Market
MEMC Electronic Materials, Inc. (WFR) announced today that four solar projects in Europe has been executed by company during the second quarter of 2012. Cash received on the closing of these transactions will be included in the company’s second quarter cash balances. MEMC Electronic Materials, Inc. 501 Pearl Drive (City of O’Fallon) St. Peters, MO […]
Aeterna Zentaris Inc. (AEZS): Put it on Watch
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced on June 28th that its Japanese partner Yakult Honsha (“Yakult”) (Tokyo: 2267) has initiated a Phase 1 trial in multiple myeloma, a form of blood cancer, with perifosine, the Company’s oral Akt/PI3K inhibitor drug. Yakult, who are sponsoring and conducting this trial in Japan, reported that a first patient […]
KB Home (KBH): Revenues Increased, Net Loss Narrows Significantly
KB Home (KBH) today reported results for its second quarter ended May 31, 2012. Highlights: Revenues totaled $302.9 million, up 11% from $271.7 million for the second quarter of 2011 Revenues up 24% in the West Coast region, 5% in the Southeast region, and 4% in the Central region for the three of the Company’s […]
Idenix Pharmaceuticals, Inc. (IDIX): Follow the Money
Idenix Pharmaceuticals, Inc. (IDIX) yesterday after market close announced results from an ongoing phase IIb study of IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV). Someone may be arguing about IDX184 efficacy judging by the number of trial patients that responded well to the initial treatment with a combination of IDX184, pegylated interferon, and […]
JA Solar Holdings (JASO): Shares Buyback
JA Solar Holdings Co., Ltd. (JASO) today announced that its board of directors has approved a share repurchase program, effective immediately, that authorizes JA Solar to repurchase up to a US$100 million worth of its issued and outstanding American Depositary Shares (“ADSs”) prior to September 30, 2012. This repurchase program is about of 50% of […]
A123 Systems (AONE): A Next-generation Lithium Ion Battery Technology
A123 Systems (AONE) today introduced Nanophosphate EXT(TM), a new lithium ion battery technology capable of operating at extreme temperatures without requiring thermal management. Nanophosphate EXT is designed to significantly reduce or eliminate the need for heating or cooling systems, which is expected to create sizeable new opportunities within the transportation and telecommunications markets, among others. […]
Keep Patriot Minefinders Inc. (PROF) on Watch
Patriot Minefinders Inc. (PROF) is the classic “promotional” set-up: read filings, examine the share volume & analyze the latest news: Patriot Minefinders Inc. (PROF) announced today the appointment of four new Directors in concert with its focus on the exploration of the La Buena mining project located 5.6 miles north of Goldcorp’s Penasquito Mine and less […]
NASDAQ’s at 52W Lows: Chelsea Therapeutics International (CHTP)
Chelsea Therapeutics International, Ltd. (CHTP) announced today that a preliminary analysis of its dose-ranging exploratory Phase II trial of CH-4051 (a non-metabolized antifolate for the treatment of rheumatoid arthritis) did not demonstrate superior efficacy to methotrexate in the dose range evaluated. Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, commented: Results of this study […]